Radiotherapy with concomitant chemotherapy (CRT) is a standard-of-care for the non-surgical management of head and neck squamous cell carcinoma (HNSCC). Unrepaired DNA double-strand breaks (DSB) are the principal lesions that determine responses in tumours and normal tissues, following treatment with radiation and/or several cytotoxic agents ([@bib21]). Error-free DSB repair is done via homologous recombination (HR) using sister chromatid DNA as a template ([@bib8]). The protein RAD51 is a key component of HR and forms foci at the site of DSBs that can be visualised using immunofluorescence ([@bib7]). HR forms one component of a complex network of DNA damage response (DDR) pathways, functional assessment of which in tumours might predict treatment sensitivity or resistance ([@bib22]).

Two studies in breast cancer have proven that RAD51 foci, as seen on immunofluorescence in tumour biopsies taken after induction of DNA damage, can be used as a functional marker of DDR ([@bib7]; [@bib11]). In addition, Graeser *et al* demonstrated that delayed HR as determined by non-resolution of RAD51 foci predict for response to neo-adjuvant chemotherapy in patients with breast cancer. To our knowledge, there have been no similar clinical studies in HNSCC. The aim of this study was to investigate if delayed HR-mediated repair of DNA DSB can be used as a predictive biomarker of response to CRT in HNSCC.

Materials and methods
=====================

Eligible patients had stage III/IV SCC of the oropharynx, with primary tumours that were visible trans-orally. All patients were scheduled to receive IC followed by CRT according to a standard regimen that has been previously described ([@bib3]; [@bib20]). Informed consent was obtained from all subjects and the relevant research and development and ethics committees approved the study.

Data on stage (AJCC 2007), smoking and human papilloma virus (HPV) status (p16 immunohistochemistry (IHC)) and response at 3 months post treatment were collected. Response at 3 months after treatment was assessed using PET-CT scans. Residual disease as diagnosed on PET-CT scans was biopsy confirmed. HPV status was confirmed using PCR with reverse transcription (RT--PCR) for E6 mRNA in the diagnostic biopsy ([@bib17]).

Study intervention
------------------

All patients underwent a punch biopsy of the primary tumour under local anaesthetic between 24--30 h after administration of platinum during the first cycle of IC. The biopsy specimen was immediately fixed in a 10% neutral buffered formalin solution (Sigma-Aldrich, St Louis, MO, USA) and transferred to the pathology department at our institution for preparation of formalin-fixed paraffin-embedded (FFPE) tumour blocks. Haematoxylin-eosin stained slides prepared from the FFPE material were reviewed by a consultant pathologist (KT) to confirm the presence of tumour. Directly contiguous slides were cut for the RAD51 and phosphorylated H2AX (*γ*H2AX) analyses. *γ*H2AX staining was performed to confirm that the biopsied tumours had been exposed to chemotherapy in concentrations sufficient to induce DNA damage.

Pre-treatment FFPE tumour blocks, that were used for primary diagnosis and hence had presence of tumour confirmed by a specialist head and neck pathologist at relevant institution were also obtained.

RAD51 immunofluorescence assay
------------------------------

The pre-treatment and post-IC tumour blocks were stained using identical procotols previously validated at our institution ([@bib7]). Irradiated FFPE mouse xenograft was used as a positive control. Immunofluorescence analysis was carried out on 3 *μ*m sections of FFPE tumour material. Following antigen retrieval by microwaving at pH 9 (DAKO pH 9 buffer) for 18 min, followed by 20 min cooling in buffer, sections were treated with Triton 0.2% for permeabilization for 20 min, washed in phosphate-buffered saline (PBS), treated with 100 μl of DNAse I (Roche) 1 : 10 000 for 1 h at 37 °C and blocked with immunofluorescence buffer (IFF; 1% bovine serum albumin, 2% fetal bovine serum; PAA gold in PBS) for 30 min at room temperature. Sections were stained with geminin antibody (10802-1-AP, ProteinTech Group). 1 : 400 in IFF for 1 h at room temperature, washed with PBS, followed by anti-rabbit Alexa488 (Invitrogen, \#A21121) conjugate 1 : 1000 in IFF for 1 h at room temperature, washed with PBS, fixed with 4% paraformaldehyde (PFA) solution for 15 min, stained with RAD51 antibody (Clone 14B4; GeneTex) 1 : 100 in IFF for 1 h at room temperature, washed with PBS, followed by anti-mouse Alexa555 conjugate (Invitrogen, \#A21429) 1 : 1000 in IFF for 1 h at room temperature, washed in PBS with 4\', 6 diamidino 2 phenylindole (DAPI; 1 : 10000) for 15 min, and sections were fixed again with 4% paraformaldehyde (Sigma-Aldrich). The protocol for *γ*H2AX staining was similar, with primary antibody 1 : 500 (phospho- Histone H2AX Ser139 Clone JBW301; Millipore) in IFF for 1 h at RT.

Scoring RAD51 foci
------------------

Images were captured on a Leica TCS confocal microscope (Leica Microsystems, Milton Keynes, Bucks, UK) set up with the laser outputs controlled via the Acousto-Optical Tunable Filter and the four collection windows using the Acousto-Optical Beam Splitter as follows; 403 nm laser (25%) window 410--483 nm, 488 nm laser (25%) window 493--538 nm, 543 nm laser (100%) window 548--628 nm and 633 nm laser (25%) window 638--700 nm. Images were collected using the microscope in sequential mode with a line average of 4 and a format of 1024 Å∼1024 pixels. The image acquisition protocol for the study samples was calibrated based on the positive control. Three investigators blinded to the time-point of the sample and all clinical data, including clinical response, counted the foci independently. The staining of nuclear foci was scored as follows. Between 100 and 500 cells in the sub-epithelial layer (invasive tumour) with any nuclear geminin staining (S-phase marker), were counted at representative areas across the section. A cell with any nuclear geminin staining was counted as being positive and in S-phase of the cell cycle. Any geminin positive cell in the sub-epithelial layer would be a proliferating cell and by definition a tumour cell. RAD51 foci were only counted in the geminin-positive cells. A cell was counted as being RAD51 positive if there was at least one distinct focus per nucleus. *γ*H2AX staining was performed on a contiguous section, with a cell at least one focus considered positive. This threshold was selected as per the previous study by [@bib7]. The mean of the foci counted by the three independent investigators was calculated. The percentage of geminin-positive cells that were also positive for RAD51 was calculated as the RAD51 score for pre-treatment and 24 h post-treatment specimens. The difference between the RAD51 score for the two specimens was then calculated. Tumour specimens with a percentage difference of ⩽10% between pre- and post-treatment specimens were deemed to have repaired the IC-induced DSBs, and were classified as RAD51 negative. The remaining patients were classified as RAD51 positive. This limit was set, as per [@bib7], before unblinding the response data.

Results
=======

Fifteen patients were recruited into the study. The pre-treatment diagnostic biopsy was unavailable for one patient and geminin immunofluorescence staining was deemed to be of insufficient quality in one post-IC biopsy sample. Therefore, 13 pairs of samples were available for detailed analysis. [Table 1](#tbl1){ref-type="table"} details the demographic data for these patients. IHC and RT--PCR were in agreement and confirmed that five tumours were HPV-negative and eight were HPV-positive.

The median RAD51 scores for the pre- and post-IC samples were 12 and 50%, respectively. Based on a cut-off of persistence of RAD51 foci at\<or \>10% above baseline, three tumours were classified as RAD51 negative (\<10%) and ten as RAD51 positive (\>10%) at 24-hours post-IC. [Figure 1](#fig1){ref-type="fig"} shows example confocal images for RAD51 negative (1A) and RAD51 positive (1B) tumours. Pre- and post-IC samples demonstrated 20% average increase in percentage of *γ*H2AX foci ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). There was no difference in the tumours samples from RAD51 negative (58% increase) and positive (52% increase) patients ([Supplementary Figures 2 and 3](#sup1){ref-type="supplementary-material"}).

Treatment outcomes at 3 months post CRT are detailed in [Table 1](#tbl1){ref-type="table"}. Complete clinical and radiological responses (CR) to CRT at this time were achieved for 10/13 (77%) patients; the remaining 3/13 (23%) patients had evidence of persistent or progressive disease (PD). All of the three patients classified as having RAD51-negative tumours had persistent or PD and the 10 patients with RAD51-positive tumours had a CR ([Table 1](#tbl1){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}). Two out of the five (40%) patients with HPV-negative disease and 100% of the patients with HPV-positive disease had RAD51-positive tumours and had a CR. All three RAD51-negative tumours with PD were HPV-negative and would have been predicted to be in the poor prognosis group according to the Ang classification ([@bib2]).

Discussion
==========

This study demonstrates that HR functional status, as determined by resolution of RAD51 foci following induction of DNA damage by platinum-containing chemotherapy, predicts treatment response after CRT for HNSCC.

We were able to classify the patients with HPV-negative tumours into responders (40%) and non-responders (60%) based on the repair of RAD51 foci of their tumours. There was no difference in the *γ*H2AX foci induction in RAD51-negative and -positive patients, indicating that the differences in the RAD51 foci were as a result of differences in tumour biology and opposed to poor chemotherapy exposure. HNSCC can be divided into good, intermediate and poor prognosis groups based on HPV status, tumour stage and smoking history ([@bib2]). Clinical trials of treatment de-escalation in the good prognosis group (HPV-positive) are currently underway ([@bib10]) and dose-intensification strategies are being explored in the poor prognosis group ([@bib6]). One approach to treatment intensification is through DDR pathway modulation, based on the high prevalence of TP53 mutations and the resulting dysfunction in downstream DDR pathways in HPV-negative HNSCC ([@bib5]). DNA DSB repair status, as determined in this study, could potentially be used as a biomarker to identify patients with RAD51 negative tumours who might benefit from DDR modulation during CRT.

All of the HPV-positive tumours in this study were RAD51 positive and had CR following treatment. This suggests that impaired DNA DSB repair might underlie significantly higher response rates observed in HPV-positive HNSCC. Previous *in vitro* studies have shown that impaired DNA DSB repair might underlie enhanced treatment sensitivity in HPV-positive HNSCC ([@bib16]; [@bib14]). Ours is the first study to provide clinical proof-of-principle for this hypothesis by assessing DSB repair in tumour biopsies before and after DNA-damaging therapy.

Previous IHC-based studies have correlated RAD51 expression to outcomes in HNSCC ([@bib4]). However, HR protein expression at a single time-point does not provide information on the HR function DSB repair following DNA damage. This can be considered to be a major drawback when considering this as a predictive biomarker for treatment personalisation. The study by [@bib7] is the only other study that assessed DSB repair following induction of DNA damage, albeit in patients with breast cancer.

The Fanconi Anaemia pathway status for tumour samples was not known. The Fanconi Anaemia pathway consists of a network of up to 15 proteins, encoded by different genes ([@bib19]). These proteins control DNA replication and mutagenic responses to endogenous and exogenous DNA damage. The functional status of this pathway can be affected by altered gene expression either through mutations or altered methylation status. Therefore, the complete characterisation of Fanconi Anaemia pathway status would have required assessment of the mutational and methylation status of all of the pathway genes. Unfortunately adequate tumour material was not available to undertake such an analyses. Not knowing the Fanconi Anaemia pathway status in these tumours can be considered a drawback of this study, nevertheless, somatic mutations in this pathway are highly uncommon in HPV-positive and HPV-negative head and neck SCC ([@bib1]; [@bib18]).

This was a pilot study with a small sample size. Therefore formal statistical tests for comparisons were not undertaken. However, we have used validated scientific methodology with adequate controls and have accounted for cell cycle (S) phase dependence of the DSB repair pathway using geminin staining. DNA damage was induced in this study by platinum-containing IC. However, the use of IC in clinical practice continues to decline, in light of evidence of only marginal benefits when compared with CRT alone ([@bib15]; [@bib13]). Therefore, it will be important to repeat this study on tumour samples taken before and after CRT. However, larger studies are required to validate our current findings and this is likely to be challenging given the invasive nature of repeated biopsies (especially during treatment). Preliminary studies have demonstrated the potential utility of analysing HR function in microRNA and circulating tumour DNA samples obtained at venesection. Such samples could be used for larger validation studies ([@bib12]; [@bib9]).

Conclusion
==========

We have demonstrated that the failure to resolve RAD51 foci following platin-induced DNA damage can be used as an index of DSB repair and can predict response following CRT for HNSCC. This assay holds promise as a potential biomarker for patient selection in trials of DDR pathway modulation. In addition, this study provides direct clinical evidence that delayed DSB repair may explain the enhanced treatment sensitivity of HPV-positive HNSCC.
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###### 

Click here for additional data file.

![**Shows typical example of confocal images with immunofluorescence for DAPI (blue, 1), geminin (green, 2) RAD51 (red, 3) and overlaid (4).** (**A**) (RAD51-negative tumours) shows similar proportion of geminin positive with Rad51 foci in post-IC compared with pre-IC images and (**B**) (RAD51-positive tumours) shows increased proportion of cells with RAD51 foci in post-IC images.](bjc2016266f1){#fig1}

![**Shows the relationship between RAD51-negative tumours (black), RAD51-positive tumours (grey), treatment response and HPV status.** X-Axis Legend: 100...=patient trial number; CR=complete response; PR=partial response/progressive disease; negative=HPV negative; and positive=HPV positive.](bjc2016266f2){#fig2}

###### Clinical characteristics, RAD 51 status and treatment response of patients

  **Trial no.**    **Stage**   **HPV status**   **Smoking status (pack years)**   **Prognostic group**   **Difference in RAD51 foci pre- and post-IC (%)**   **RAD 51 status**   **Treatment response**
  --------------- ----------- ---------------- --------------------------------- ---------------------- --------------------------------------------------- ------------------- ------------------------
  1002               T2N2B          −ve                       30                          Poor                                  31                               Positive                  CR
  1003               T4N2B          +ve                       20                      Intermediate                              25                               Positive                  CR
  1004               T4N2B          −ve                       40                          Poor                                   7                               Negative                  PR
  1005               T2N2B          −ve                       20                          Poor                                   3                               Negative                  PR
  1006               T2N2B          +ve                      Never                        Good                                  62                               Positive                  CR
  1007               T2N1           +ve                      Never                        Good                                  44                               Positive                  CR
  1008               T3N2B          +ve                       30                      Intermediate                              71                               Positive                  CR
  1009               T3N0           +ve                       15                          Good                                  74                               Positive                  CR
  1010               T4N2C          +ve                       30                      Intermediate                              27                               Positive                  CR
  1011               T3N2B          +ve                       30                      Intermediate                              72                               Positive                  CR
  1013               T4N2B          −ve                       40                          Poor                                   3                               Negative                  PR
  1014               T2N2B          −ve                       40                          Poor                                  27                               Positive                  CR
  1015               T3N2B          +ve                      Never                        Good                                  57                               Positive                  CR

Abbreviations: CR=complete response; HPV=human papilloma virus; PR=partial response.
